Novartis Pharmaceuticals Corp. v. Noven Pharmaceuticals, Inc.
125 F. Supp. 3d 474
D. Del.2015Background
- Novartis sued Noven alleging infringement of U.S. Patent No. 6,335,031 (claims 7 and 16 asserted); parties stipulated infringement but disputed validity.
- Claims at issue relate to a transdermal device (claim 7) and a stabilization method (claim 16) for (S)-rivastigmine that require inclusion of specified antioxidants.
- Noven defended by asserting obviousness under 35 U.S.C. § 103(a) and obviousness-type double patenting, relying on prior art and arguments that a PHOSITA would expect rivastigmine to undergo oxidative degradation and thus to add antioxidants.
- The court conducted a three-day bench trial on validity and required Noven to prove invalidity by clear and convincing evidence.
- The court found that (1) a PHOSITA in January 1998 would not have known rivastigmine was susceptible to oxidative degradation based on its structure or comparison to nicotine, (2) none of the asserted prior-art references disclosed that susceptibility, and (3) therefore Noven failed to prove obviousness or obviousness-type double patenting.
Issues
| Issue | Plaintiff's Argument (Novartis) | Defendant's Argument (Noven) | Held |
|---|---|---|---|
| Obviousness of claims 7 & 16 | Rivastigmine’s stability was not known; discovery that it oxidizes and that antioxidants stabilize it was inventive | A PHOSITA would have known rivastigmine is susceptible to oxidation from structure and similarity to nicotine; prior art would motivate adding antioxidants | Held: Not obvious — Noven failed to prove by clear and convincing evidence that a PHOSITA would have known rivastigmine oxidizes or been motivated with a reasonable expectation of success to add antioxidants |
| Reliance on chemical-structure reasoning | Structure alone does not establish actual instability; testing is required | Structural features (benzylic/tertiary sites, adjacent amine/aromatic) predict susceptibility to oxidation | Held: Structure alone insufficient; no prior art testing or publications showed rivastigmine instability prior to 1998 |
| Comparison to nicotine | Structural differences are significant; cannot extrapolate stability from nicotine | Nicotine was known to oxidize; similarities would create expectation rivastigmine would too | Held: Rivastigmine and nicotine not sufficiently similar to give PHOSITA expectation of similar oxidative behavior |
| Obviousness-type double patenting vs. U.S. Patent No. 5,602,176 | Addition of antioxidant renders claims patentably distinct; patents not commonly owned/inventive entity differs | 176 patent claims render later claims obvious improvement and common ownership exists (Novartis AG common assignee) | Held: No double patenting — prior art (176/GB) did not disclose rivastigmine’s oxidative susceptibility, claims are patentably distinct; also common ownership/inventor criteria not met |
Key Cases Cited
- KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398 (explains obviousness framework and predictable use of prior art elements)
- Transocean Offshore Deepwater Drilling, Inc. v. Maersk Drilling USA, Inc., 699 F.3d 1340 (Federal Circuit discussion of factual inquiries for obviousness)
- Allergan, Inc. v. Sandoz Inc., 726 F.3d 1286 (motivation-to-combine and reasonable expectation of success requirements)
- In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litig., 676 F.3d 1063 (standards for obvious-to-try evidence and finite options)
- In re Hubbell, 709 F.3d 1140 (obviousness-type double patenting doctrine and ownership considerations)
- AbbVie Inc. v. Mathilda & Terence Kennedy Inst. of Rheumatology Trust, 764 F.3d 1366 (two-step analysis for double patenting: claim differences and patentable distinctness)
- Geneva Pharms., Inc. v. GlaxoSmithKline PLC, 349 F.3d 1373 (distinctions between statutory obviousness and nonstatutory double patenting)
- Leo Pharm. Prods., Ltd. v. Rea, 726 F.3d 1346 (recognition that an undiscovered problem persisting in prior art supports nonobviousness)
- Novartis Pharm. Corp. v. Par Pharm., Inc., 48 F. Supp. 3d 733 (prior district decision by this court addressing similar questions of rivastigmine stability)